| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Division of Pulmonary/Critical Care Medicine, Pennsylvania State University at the Milton S. Hershey Medical Center, Hershey, Pa.
Study objective: To evaluate the impact of a week-long course of inhaled albuterol compared with ipratropium on expiratory peak flow, exercise performance, and dyspnea in patients with stable COPD.
Design and interventions: A double-blind, two-period, crossover evaluation, wherein the subjects inhaled albuterol, two puffs four times a day (qid) for 7 days, or ipratropium, two puffs qid for 7 days, in random sequence.
Setting: Outpatients of the Pennsylvania State University Hospital, Lebanon VA Medical Center, and local private office practices.
Participants: A sample of 15 subjects with stable COPD with FEV1 <55% predicted.
Measurements and results: Variables measured at baseline (no inhaled bronchodilator) and/or on day 7 of each arm included FEV1 (liters), 12-min walk test distance (meters), "rescue" puffs of metaproterenol needed each week, and dyspnea scoring after walking, on the Borg Category Scale (0 to 10=maximal). There was no significant difference in distance walked in 12 min (mean of 751.0±55.5 [±SE]) vs 755.7±61.3 m) or perceived dyspnea (mean 2.7±0.4 vs 3.3±0.4) during albuterol or ipratropium use. Seven patients preferred ipratropium, seven preferred albuterol, and one had no preference.
Conclusion: We conclude that the effects of 1 week of albuterol or ipratropium have similar effects on exercise performance and subjective dyspiea in patients with stable COPD.
Key Words: bronchodilators • COPD • dyspnea • exercise tolerance
Submitted on August 9, 1994
Accepted on April 3, 1995
This article has been cited by other articles:
|
|
 |
|
  T. Oga, K. Nishimura, M. Tsukino, S. Sato, T. Hajiro, and M. Mishima A Comparison of the Effects of Salbutamol and Ipratropium Bromide on Exercise Endurance in Patients With COPD Chest, June 1, 2003; 123(6): 1810 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Troosters, J. Vilaro, R. Rabinovich, A. Casas, J.A. Barbera, R. Rodriguez-Roisin, and J. Roca Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease Eur. Respir. J., September 1, 2002; 20(3): 564 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. W. Liesker, P. J. Wijkstra, N. H. T. Ten Hacken, G. H. Koeter, D. S. Postma, and H. A. M. Kerstjens A Systematic Review of the Effects of Bronchodilators on Exercise Capacity in Patients With COPD Chest, February 1, 2002; 121(2): 597 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler, J. F. Donohue, R. A. Barbee, M. D. Goldman, N. J. Gross, M. E. Wisniewski, S. W. Yancey, B. A. Zakes, K. A. Rickard, and W. H. Anderson Efficacy of Salmeterol Xinafoate in the Treatment of COPD Chest, April 1, 1999; 115(4): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Saito, K. Miyamoto, M. Nishimura, A. Aida, H. Saito, I. Tsujino, and Y. Kawakami Effects of Inhaled Bronchodilators on Pulmonary Hemodynamics at Rest and During Exercise in Patients With COPD Chest, February 1, 1999; 115(2): 376 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ALBUTEROL VS. IPRATROPIUM FOR COPD Journal Watch (General), October 3, 1995; 1995(1003): 3 - 3. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
